Mylan announced Celgene will pay it US$62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.
Mylan disclosed the settlement in a filing with the US Securities and Exchange Commission on Monday, July 29, days after Celgene agreed to pay US$55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.44
Please verify email or join us
to access premium content!
